# Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults

> **NCT02333591** · PHASE4 · COMPLETED · sponsor: **Mette Zander** · enrollment: 25 (actual)

## Conditions studied

- Coronary Microvascular Dysfunction

## Interventions

- **DRUG:** GlucagonLikePeptide-1 (7-36)
- **DRUG:** GlucagonLikePeptide-1 (9-36)
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT02333591
- **Lead sponsor:** Mette Zander
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333591, "Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02333591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*